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ABSTRACT  
Here, we introduce a novel scFv antibody, G2-D11, specific for two adjacent Tn-antigens (GalNAc-
Ser/Thr) binding equally to three dimeric forms of the epitope, Ser-Thr, Thr-Thr and Thr-Ser. 
Compared to other anti-Tn reagents, the binding of G2-D11 is minimally influenced by the peptide 
structure, which indicates a high degree of carbohydrate epitope dominance and a low influence 
from the protein backbone. With a high affinity (KDapp = 1.3 × 10
−8
 M) and no cross-reactivity to 
either sialyl-Tn epitope or blood group A antigens, scFv G2-D11 is an excellent candidate for a well-
defined anti-Tn-antigen reagent. Detailed immunohistochemical evaluation of tissue sections from 
a cohort of 80 patients with gastric carcinoma showed in all cases positive tumor cells. The 
observed staining was localized to the cytoplasm and in some cases to the membrane, whereas the 
surrounding tissue was completely negative demonstrating the usefulness of the novel Tn-antigen 
binding antibody. 
INTRODUCTION  
A common O-linked glycosylation with N-acetylgalactosamine (GalNAc) occurs at serine (Ser) or 
threonine (Thr) residues of glycoproteins and is known as the Tn-antigen. The Tn-antigen is the 
precursor for extended O-glycans and is shielded by the elongated structures in healthy and benign 
tissues. Cancer cells often have an altered glycosylation biosynthesis leading to the expression of 
aberrant carbohydrate structures on the cell surface (Gill et al. 2010; Pinho and Reis 2015). These 
modified glycans play a role in intercellular recognition and adhesion, as well as in tumor invasion 
and metastasis (Pinho and Reis 2015). Truncated glycan structures, like the Tn-antigen, have been 
associated with a variety of human carcinomas, e.g., colon, breast, lung, bladder, cervix, ovarian, 
stomach and prostate cancer (Hamada et al. 1993; Desai 2000; Oshikiri et al. 2006). The Tn-antigen 
is present on many different proteins. Different mucins in carcinomas carry a high density of Tn-
antigens (Ju et al. 2011) and leukemic cells have been found to carry Tn-antigen on CD43 
(sialophorin) (Nakada et al. 1991). The IgA1 immunoglobulin, with a hinge region that can carry the 
Tn-antigen, is believed to be involved in autoimmune disease (Tomana et al. 1999) and has also 
been associated with breast cancer (Welinder et al. 2013). These tumor-associated antigens, which 
are ectopically expressed in cancer cells, could be used as potential targets for both diagnosis and 
therapy (Avichezer et al. 1997; Springer 1997; Yu 2007; Welinder et al. 2011; Posey et al. 2016). 
A number of antibodies with different specificities for the Tn-antigen have been generated 
(Takahashi et al. 1988; Numata et al. 1990; Pancino et al. 1990; Avichezer et al. 1997; Reis et al. 
1998; Ando et al. 2008). Many of these Tn-specific monoclonal antibodies (mAbs) recognized 
clusters composed of two or three consecutive glycosylated Ser/Thr residues. In some cases, the 
antibody is dependent on the peptide sequence of the glycoprotein and thereby recognizing a 
glycopeptide-specific epitope (Reis et al. 1998; Brooks et al. 2010; Blixt et al. 2012b). Many different 
anti-Tn antibodies have been used for immunohistochemistry (IHC) evaluation (Ohshio et al. 
1995; Zhang et al. 1998; Welinder et al. 2011) with varying outcome, regarding both the intensity 
and the frequency of Tn-expression. This was clearly illustrated in a prostate cancer study, where 
the IHC results of four different Tn-binding reagents were compared with carbohydrate microarray 
analysis (Li et al. 2009). The fine specificity was shown to differ between the Tn-binding reagents 
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with a preference for clustered Tn-antigens, but with reagents also recognizing the single Tn-
antigen or demonstrating cross-reactivity to blood group A (Li et al. 2009). 
The complexity of the Tn-antigen increases with the possibility of O-GalNAc to be associated with 
either serine or threonine and with the mono- or multimeric formations on proteins. These details 
will influence the flexibility and overall global shape of the glycoprotein and the binding of lectins 
(Madariaga et al. 2014, 2015). 
The evaluation of antibody specificity is an essential part in the development of antibodies to be 
used for diagnosis or therapy. In this study, we have analyzed the fine specificity of a new single-
chain fragment variable (scFv) antibody, G2-D11, with two glycopeptide libraries, one based on 
trimer and one on 20-mer peptides, presenting GalNAc-Ser and GalNAc-Thr in different 
combinations. In a cohort of gastric carcinoma, the staining of the cytoplasm and, in some cases, 
the membrane was observed with the G2-D11. The different staining pattern between gastric 
carcinoma with cytoplasmic and membrane staining and adjacent mucosa with perinuclear 
staining, indicate that G2-D11 could be used as a tool for diagnostic and therapeutic purpose. 
RESULTS 
Tn-peptide microarray library 
G2-D11 is one of the Tn-antigen binding scFvs obtained from an antibody phage library generated 
from mice immunized with glycopeptides as previously described (Persson et al. 2016). To evaluate 
the specificity of G2-D11, a large synthetic glycopeptide library was constructed and printed on 
microarray glass slides. The library contained trimer amino acid combinations of GalNAc-Ser (S*) 
and GalNAc-Thr (T*) flanked by different combinations of amino acids (X). The library was 
organized into five groups, depending on the position of the GalNAc on either Ser or Thr residues. 
Group 1 consisted of two GalNAc-Thr residues at the C-terminal end. Group 2 consisted of two 
GalNAc-Thr residues at the N-terminal, and Group 3 started with one amino acid without 
glycosylation, followed by one GalNAc-Thr and one GalNAc-Ser residue. Group 4 consisted of an N-
terminal GalNAc-Ser and a GalNAc-Thr residue followed by a C-terminal amino acid, and Group 5 
had a nonglycosylated amino acid on both sides of a single GalNAc-Thr residue (Figure 1). The Vicia 
villosa lectin (VVL) binds both mono- and multimeric forms of the Tn-antigen (Osinaga et al. 
2000; Wu 2004) and is used as a control for surface immobilization of all synthetic Tn-glycopeptides 
(Figure 2). 
Specificity analysis 
Previously published mouse monoclonal Tn antibodies, GOD3-2C4 (Welinder et al. 2013), MLS128 
(Ohshio et al. 1995) and the scFv version of GOD3-2C4 (sH1), were compared with G2-D11 for 
binding to the trimer glycopeptide library (Figure 2). Both G2-D11 and GOD3-2C4 bound to two 
adjacent Tn-antigens flanked by most amino acid combinations. In Group 1, which included two 
adjacent GalNAc-Thr residues, the presence of proline (Pro) and glutamic acid (Glu) residues 
reduced the binding of G2-D11 (Figure 2A, circled in red). MLS128 was more sensitive to the amino 
acid present next to the two adjacent GalNAc-Thr residues. A binding similar to the ones seen with 
G2-D11 and GOD3-2C4 could only be observed for the amino acids cysteine (Cys), lysine (Lys), 
arginine (Arg) and tryptophan (Trp) (Figure 2A, circled in red). 
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When changing the position of the amino acid residues to the C-terminal side of the two adjacent 
GalNAc-Thr residues (represented by Group 2), G2-D11 and GOD3-2C4 still bound to the most 
amino acid combinations, but both were affected by the amino acids leucine (Leu) and glycine (Gly) 
and additionally valine (Val), and isoleucine (Ile) for GOD3-2C4 (Figure 2B, circled in red). Most of 
the amino acid combinations reduced the binding of MLS128, showing only elevated binding for Glu 
(Figure 2B, circled in red). 
When one of the GalNAc-Thr residues was exchanged with a GalNAc-Ser residue in Group 3, the 
G2-D11 and GOD3-2C4 still bound to most of the combinations, but neighboring amino acids, 
particularly Glu and glutamine (Gln) prevented the binding of G2-D11 (Figure 2C, circled in red). No 
binding could be seen with MLS128 with the exception of amino acid Trp (Figure 2C, circled in red). 
In Group 4, G2-D11 bound to all amino acid combinations while the binding of GOD3-2C4 was 
reduced by Glu (Figure 2D, circled in red). With the GalNAc-Ser/GalNAc-Thr in Group 4, MLS128 
showed slightly elevated signals compared to GalNAc-Thr/GalNAc-Ser in Group 3 and bound only 
weakly to Arg (Figure 2D, circled in red). In Group 5, different combinations with single GalNAc-Thr 
were tested. Only GOD3-2C4 and G2-D11 showed some binding events (Figure 2E and F, circled in 
red) in the representative graphs of different monomeric Tn-antigen combinations. G2-D11 bound 
to a few combinations containing Trp, tyrosine (Tyr) and alanine (Ala) while GOD3-2C4 bound to 
many combinations with Trp and to some with Tyr and phenylalanine (Phe). The sH1 showed low 
binding to all of the Group 1–5a, b (Figure 2). 
A second glycopeptide library was used to evaluate the specificity based on a titration of the 
antibodies and consisted of tetra- and 20-mer glycopeptides, 20-mers of mucin-1 (Muc1) with sialyl-
Tn-antigen (STn-antigen) and blood group A antigen (Table I). The library was printed on a 
microarray slide and evaluated using G2-D11, sH1, GOD3-2C4 and MLS128 at different 
concentrations (Figure 3A). The anti-STn-antigen antibodies, B72.3 and CC49, were used as positive 
controls for STn-antigen on Muc1 (peptide 24 and 25; Figure 3B). The previous microarray result, 
where G2-D11 bound to two adjacent GalNAc-epitopes, was confirmed (Table I, peptides 1, 2, 9, 
12, 13, 14, 18, 19 and 20; Figure 3A). At higher concentrations, the sH1 scFv bound to two adjacent 
GalNAc-epitopes in combination S*T* (peptide 9, 18 and 19), but not to any of the single GalNAc 
epitopes (Figure 3A). The GOD3-2C4 also bound a single GalNAc-Ser residue, besides binding two 
or three adjacent GalNAc epitopes (peptides 3, 6, 7, 10 and 21), but also demonstrated cross-
reactivity with the blood group A antigen (peptide 26) (Figure 3A). Unlike GOD3-2C4, MLS128 did 
not bind single GalNAc epitopes and preferred two or three adjacent GalNAc-epitopes on 20-mer 
peptides to tetramer epitopes (peptides 1, 9, 12, 18 and 19) (Figure 3A). None of the antibodies G2-
D11, sH1, GOD3-2C4 or MLS128 were cross-reactive with the STn-antigen (Figure 3A). Both anti-
STn antibodies, B72.3 and CC49, showed cross-reactivity to the Tn-antigen (peptides 1, 9, 
18 and 19), but clearly preferred the STn-epitope (peptide 24 and 25) at these assay conditions 
(Figure 3B). The Tn-binding antibodies were also analyzed for binding to two adjacent GalNAc-
serines on the CD44-peptide WVNRGESSRKAYDHNSPY (Supplementary data, Figure S1). Only G2-
D11 and GOD3-2C4 bound to the glycopeptide while sH1 and MLS128 were negative. G2-D11 did 
not bind any other related carbohydrate structures (e.g., GalNAcβ, GalNAcα1-3GalNAcα, 
GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ, GlcNAcα, GlcNAcβ) tested on a large carbohydrate 
microarray chip and no binding to other carbohydrate or single GalNAc epitope was observed (data 
not shown; a list of the tested carbohydrates is presented in Supplementary data, Table S1). GOD3-
2C4 demonstrated cross-reactivity to GalNAcα1-3Galβ-, Core 5, Core 6, Galβ1-4GlcNAcβ1-
6GalNAcα- and GalNAcα1-3GalNAc(fur) β- (data not shown). 
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Analysis of binding kinetics 
The analysis of binding kinetics of G2-D11 to two adjacent GalNAc on a 20-mer peptide (Table I, 
peptide 9) was made with bio-layer interferometry (BLI). Two different approaches were tested to 
measure the on- and off-rates to calculate a dissociation constant. In the first approach, the 
biotinylated target peptide was immobilized on streptavidin sensor tips and in the second 
approach, the G2-D11 and sH1 were immobilized on nickel-nitrilotriacetic acid (Ni-NTA) sensor tips 
through their histidine (His)-tags. Using either of the two methods, the G2-D11 dissociation 
constant was determined to be in the nanomolar range (Table II, complete sensogram 
in Supplementary data, Figure S2). GOD3-2C4 had a dissociation constant in the same range as G2-
D11, but was only analyzed with immobilized glycopeptide as it lacks the His-tag. The sH1 
generated a weak signal that did not fit the 1:1 Langmuir model and no conclusion could be drawn 
from the analysis by either methods. 
Immunofluorescence staining of MKN45 cells 
We used the gastric carcinoma cell line MKN45, stably transfected with ST6GALNAC1, as a model to 
evaluate antibody binding in a relevant biological context. This cell line has previously been 
described to overexpress STn-antigen compared to the mock control cell line transfected with an 
empty vector (Marcos et al. 2004). Fixed mock and ST6GALNAC1transfected MKN45 cells were 
incubated with G2-D11, sH1 or GOD3-2C4. Both GOD3-2C4 and G2-D11 showed punctuated 
intracellular staining in the mock transfected cells and sH1 showed a much weaker staining 
(Figure 4A). GOD3-2C4 showed increased cytoplasmic staining with indications of membranous 
staining in the ST6GALNAC1transfected cells in contrast to G2-D11, which maintained the 
punctuated intracellular staining pattern (Figure 4A). The ST6GALNAC1 transfected cells were 
treated with neuraminidase which significantly reduced binding of the anti-STn antibody, B73.2 
(Figure 4B). The staining of the Tn-antigen with G2-D11 was seen to change from the punctuated 
intracellular staining in the nonneuraminidase-treated cells to increased diffuse cytoplasmic 
staining with indications of membranous staining in the neuraminidase-treated cells (Figure 4B). 
IHC analysis 
The staining of G2-D11 was compared to the staining of GOD3-2C4 and sH1 on a series of human 
gastric carcinoma using IHC where 1E3 was used as a positive control (Figure 5) (Blixt et al. 2012a). 
In intestinal metaplasia, a premalignant condition, the G2-D11 stained specifically the perinuclear 
region correlating with Golgi apparatus of the cells. The GOD3-2C4 also stained the vacuoles of 
goblet cells in intestinal metaplasia. These vacuoles are rich in mature mucins, mostly mucin-2 
carrying STn-antigen (Ferreira et al. 2006). The staining of carcinoma cells with G2-D11 and GOD3-
2C4 was not restricted only to the perinuclear compartments but was found in the cytoplasm, in the 
cellular membrane and also on secreted glycoproteins in the mucin lakes. In addition, G2-D11 
stained larger tumor areas and with higher intensity than GOD3-2C4. The staining with sH1 was 
very weak in all parts of the tissue. All the tested antibodies showed staining exclusively in epithelial 
and carcinoma cells. 
Formalin fixed paraffin embedded tissue sections from a cohort of 80 patients with gastric 
carcinoma were all stained positive in IHC with G2-D11. The antibody gave a clear image with low 
background and intense tumor staining (Figure 6). Frequency and intensity of staining in tumor and 
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adjacent mucosa are presented in Table III and Figure 6. The staining was mainly localized to 
perinuclear in the adjacent mucosa (73%, Figure 6A) and in some cases a cytoplasmic staining could 
also be seen (Figure 6B). In all cases, tumor cells showed mainly cytoplasmic staining (Table III, 
Figure 6C and D) and 24 cases had more than 75% of the tumor area stained with medium (++) to 
high intensity (+++). A clear enriched staining at the cancer cell membrane could be seen in seven 
cases (Figure 6E and F). In 22 of the 25 cases that presented mucin lakes within the tumor area, the 
mucin lakes were stained with G2-D11 (Figure 6G). This indicates a frequent ectopic expression of 
the Tn epitope in the secretome and a good sensitivity of G2-D11 to detect the mucin lakes. 
DISCUSSION 
In this study, we have performed an extended analysis of the epitope defined by a new anti-Tn-
antigen antibody, G2-D11, using different microarray analysis, affinity measuring as well as 
immunofluorescence staining on gastric cancer cell lines and IHC on tissues from patients with 
gastric carcinoma. 
The G2-D11 antibody bound specifically to two adjacent Tn-antigens independently of their 
different positions on Ser and Thr residues, and with low influence from surrounding amino acids 
(Figures 2 and 3). It bound weakly to single GalNAc-Ser but not to STn-antigen. In contrast to 
GOD3-2C4 and MLS128, G2-D11 did not show any cross-reactivity to the blood group A antigen. 
Additionally, to the specificity evaluation of G2-D11, an extensive binding kinetics analysis was 
performed. When using, techniques involving immobilization, the interacting part in solution must 
be of monovalent nature to avoid artifacts due to the multivalent binding. The most common way 
of analyzing the binding constant involves immobilization of the antigen but when analyzing 
bivalent or dimeric antibodies there is a risk of measuring avidity instead of affinity. For kinetic 
binding analysis, two different setups were used in this study. The first involved immobilization of 
biotinylated antigen on streptavidin biosensors and in the second, the histidine-tag of scFv was 
used for immobilization on Ni-NTA biosensors. The binding kinetics data for G2-D11 resulted in 
similar on- and off-rates (reflecting how fast the antibody binds to or dissociate from the target) for 
both setups, indicating that the analysis was not affected by multimerization and an 
apparent KD value in the nanomolar range (10
−8
) could be calculated (Table II). The G2-D11 
demonstrated an affinity constant in the same range as IgG, GOD3-2C4 and MLS128, and the IgM 
83D4 (Osinaga et al. 2000) and a 10- to 100-fold higher affinity constant compared to previously 
described Tn-antigen binding scFv, 4E10, 4G2 and scFv of MLS128, which show KD values in the 
micromolar range (10
−6
) (Sakai et al. 2010; Yuasa et al. 2012). The binding kinetics data for sH1 
could not be evaluated since the sensogram differed from the 1:1 curve fitting model. Since sH1 is 
the scFv version of IgG1 GOD3-2C4, it is expected to bind the same antigen but with lower affinity. 
Both the BLI analysis and the microarray analysis indicate that sH1 binds to the target antigen but 
with a weak interaction. This could be due the monovalent binding of scFv compared to the 
multivalent binding of GOD3-2C4 or to partly changed structure of scFv upon expression compared 
to GOD3-2C4. 
A diffuse cytoplasmic and membranous staining pattern of MKN45 cells transfected with 
ST6GALNAC1 have previously been seen by two Tn-binding antibodies, 1E3 and HB-Tn (Pinho et al. 
2007). The punctuated cytoplasmic staining of mock transfected MKN45 cells was observed for 
both G2-D11 and GOD3-2C4 (Figure 4A), similar to the staining of Golgi seen by anti-Tn antibody on 
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HeLa cells after EGF treatment (Gill et al. 2010). The ST6GALNAC1 transfected cells showed a more 
diffuse cytoplasmic staining by GOD3-2C4, as compared to mock transfected cells (Figure 4A). In 
contrast, the subcellular localization of G2-D11 binding was not affected by the overexpression 
of ST6GALNAC1. The Tn-antigen specificity of G2-D11 was verified when the staining 
of ST6GALNAC1transfected MKN45 cells was increased and changed to diffuse cytoplasmic staining 
with indications of membraneous staining after neuraminidase treatment. This resembles the B72.3 
staining of nontreated cells and correlates with the change from STn- to Tn-antigen. The B72.3 
staining of ST6GALNAC1 transfected cells was reduced with neuraminidase demonstrating that 
B72.3 prefers the STn-epitope. This binding is probably due to higher affinity for STn-antigen than 
Tn-antigen as the microarray analysis resulted in a binding to Tn-antigen at high concentrations. 
Previously it was shown that different Tn-antigen binding antibodies stain prostate cancer (Li et al. 
2009), colon and breast cancer (Mazal et al. 2013) with different intensity and frequency. This is 
probably due to their differences in fine specificity, affinity or cross-reactivity. In this study, tissues 
from gastric carcinoma were used for comparing the staining pattern of G2-D11 with GOD3-2C4, 
sH1 and 1E3 (Figure 5). Both major histological subtypes, intestinal and diffuse, were included in the 
comparison which commonly also included adjacent gastric mucosa and adjacent premalignant 
lesions such as dysplasia, hyperplasia and intestinal metaplasia. Briefly, all antibodies, except sH1, 
stained perinuclear adjacent premalignant lesions and normal adjacent gastric mucosa. Perinuclear 
staining has been reported with MLS128 in normal columnar epithelium (Ohshio et al. 1995). The 
perinuclear stain, seen in Figure 5A and B, is believed to be associated mainly with Golgi, a place for 
the majority of O-glycosylation. In cancer, altered expression of glycosyltransferases and relocation 
of transferases from Golgi into the ER lead to change in the pattern of O-glycosylation and also 
correlates with increased migration and a metastatic behavior of the tumor. The spread of staining 
in IHC to cytoplasm and plasma membrane indicate an increase in the presence of different proteins 
carrying the bis-Tn epitope. GOD3-2C4 stained the vacuoles of goblet cells in intestinal metaplasia, 
indicating that the goblet cells, in addition to high expression of STn-antigen (Ferreira et al. 
2006; Conze et al. 2009), may also express the Tn epitope. The difference in staining pattern could 
relate to the specificity of the antibody, where G2-D11 bind to all combinations of two adjacent Tn-
antigens regardless of peptide backbone and GOD3-2C4 recognizes additional epitopes such as 
single Tn-antigen and blood group A antigen. 
Staining of tissue sections from 80 cases of gastric carcinoma confirms the preliminary results from 
the comparison of the Tn-antibodies (Figure 5), showing perinuclear staining of adjacent mucosa. 
Moreover, we confirmed in all carcinoma cases the ectopic diffuse cytoplasmic staining (Table III) 
which has also been reported for MLS128 in stomach adenocarcinoma (Ohshio et al. 1995). The G2-
D11 has increased sensitivity in gastric carcinomas to detect Tn-antigen compared to GOD3-2C4 or 
other anti-Tn mAbs (Figure 5). The detection of secreted proteins as demonstrated in the mucin 
lakes (Table III and Figure 6) and the absence of staining of secretory vacuoles in premalignant 
lesions (Figure 5), render G2-D11 as a candidate for biomarker detection to be used in IHC. 
In conclusion, G2-D11 is a high affinity antibody specific for the bis-Tn epitope (two adjacent O-
GalNAc) independent of the carrier protein. The antibody's fine specificity results in a clear 
difference between IHC staining patterns of tumor area and adjacent mucosa. This should make 
G2-D11 useful as a highly specific reagent for detection of bis-Tn epitope (Tn2) in biological 
samples. 
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MATERIALS AND METHODS 
Materials 
General chemicals were purchased from Sigma-Aldrich (Denmark). The Fmoc (9-
fluorenylmethyloxycarbonyl)-protected amino acids, MeOH, N-methyl-2-pyrrolidone, N,N-
dimethylformamide, piperidine, trifluoroacetic acid, N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-methylmethan-aminium-hexafluoro-phosphate-N-oxide, and 1-
Hydroxy-7-azabenzotriazole were purchased from Iris Biotech GmbH (Marktredwitz, Germany). N-
α-Fmoc-O-β-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-galactopyranosyl)-L-serine (Fmoc-
Ser(β-D-GalNAc(Ac)3)-OH) and N-α-Fmoc-O-β-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-β-D-
galactopyranosyl)-L-threonine (Fmoc-Thr(β-D-GalNAc(Ac)3)-OH) were purchased from Sussex 
Research Laboratories, Inc. (Ontario Canada). Monoclonal antibodies GOD3-2C4 (Welinder et al. 
2011), MLS128 binding to Tn-antigen (Cat. No #017-25,891, Wako), B72.3 binding to STn-antigen 
(Cat. No ab691, abcam) and also used as hybridoma supernatant, and CC49 binding to STn-antigen 
(Cat. No ab16838, abcam) were used in this study. ScFv G2-D11 was isolated from an antibody 
phage library obtained from mice immunized with glycopeptides, as previously described (Persson 
et al. 2016). ScFv sH1 is a codon-optimized (GeneArt) scFv derivative of GOD3-2C4 (Welinder et al. 
2011) expressed as previously described (Persson et al. 2016). Bovine serum albumin (BSA) 
conjugated blood group A antigen was kindly provided by Prof. T. Boren, Umeå. The glycans for 
glycan array are produced as previously described (Frederiksen et al. 2015). 
Glycopeptide and peptide synthesis 
All peptides and glycopeptides were prepared by standard Fmoc solid-phase peptide synthesis on 
an automated Syro I peptide synthesizer (Biotage AB, Sweden), as previously described (Blixt et al. 
2010; Blixt and Cló 2013) with some modifications (protocols are presented in Supplementary data 
SI). Synthesis was carried out on TentaGel S Rink Amide Resin with a loading density of 0.24 
mmol/g (Rapp Polymers GmbH, Germany) with Fmoc for protection of N
α
-amino groups; sidechain 
protecting groups were tert-butyl (for Ser, Thr, Glu, Asp), 2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl (Pbf, for Arg), tert-butyloxycarbonyl (Boc for Lys), and 
triphenylmethyl (trityl for Asn, Gln, His). For glycopeptide identification, peptides 1–11and random 
samples of the trimer library and of the tip synthesis of CD44-peptide were analyzed by 
electrospray ionization mass spectrometry (ESI-MS) (MSQ Plus Mass Spectrometer, Thermo). 
Purity (>95%) was evaluated by analytical HPLC (Dionex Ultimate 3000 system) on an analytical C18 
column (Phenomenex Gemini NX 110 Å, 5 μm, C18 particles, 4.60 × 50 mm) using a linear gradient 
flow of water-methanol containing 0.1% formic acid (5–100% MeOH in 15 min). 
Microarray preparation and analysis 
The peptides and the glycopeptides were diluted in print buffer (300 mM phosphate buffer, pH 8.5) 
to 100 μM for purified material and 1/20 of crude material. The peptides were printed by robotic pin 
deposition using a MicroGrid II arrayer (BioRobotics, Genomics Solutions, quilled pins, 250 μm 
pitch) onto N-hydroxysuccinimide (NHS)-activated glass array slides (SCHOTT NEXTERION® Slide 
H) (Blixt et al. 2010; Blixt and Cló 2013). The printed slides were placed in a high-humidity chamber 
for 1 hour. The remaining NHS groups were blocked by immersion in NHS blocking buffer (50 mM 
ethanolamine in 50 mM borate buffer, pH 9.2) for 30 min just before use. The slides were incubated 
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with the primary antibody for 1 h with agitation at room temperature (RT) and washed three times 
with phosphate-buffered saline (PBS). Mouse anti-His antibody (3 μg/mL) was added and incubated 
for 1 hour with agitation at RT, followed by detection with the secondary antibody, Cy5-conjugated 
goat anti-mouse IgG (H+L) (Jackson ImmunoResearch Labs, Cat. no 115-175-146) diluted 1:500 in 
PBS, and incubated for 1 h at RT. All incubation steps were separated by three washing steps with 
PBS. After the final washing step, the slides were rinsed in water and air dried. The fluorescence 
signal was measured using a ScanArray 5000 (PerkinElmer) confocal scanner. 
Binding kinetics evaluation 
OctetRed96 (ForteBio, Menlo Park, CA, USA) was used for BLI studies. Samples and buffers were 
dispensed into polypropylene 96-well black flat-bottom plates (Greiner Bio-One, Frickenhausen, 
Germany) at a volume of 200 μL per well, and all measurements were performed at 30°C with 
agitation at 1000 rpm. Prior to each assay, streptavidin biosensor tips (ForteBio) and Ni-NTA 
biosensor tips (Fortebio) were prewetted in PBS for at least 10 min followed by equilibration with 
PBS. The streptavidin biosensor tips were noncovalently loaded with biotinylated IgA1 glycopeptide 
(Peptide 9, Table I) in PBS with binding kinetics buffer (Fortebio), followed by an additional 
equilibration step. Association of mAbs in a range of different concentration was performed for 300 
s. Finally, the dissociation was monitored with PBS containing binding kinetics buffer for 300 s. The 
Ni-NTA biosensor tips were loaded with histidine-tagged scFv (6.25 μg/mL) in PBS with binding 
kinetics buffer (Fortebio), followed by an additional equilibration step. Association of glycopeptides 
at different concentrations was performed for 60 s. Finally, the dissociation was monitored with 
PBS containing binding kinetics buffer for 60 s. All measurements were performed in triplicates. 
The association and dissociation responses were processed with the Octet Software (Version 7.0 
and 7.1, ForteBio). Interferometry data was globally fitted to a simple 1:1 Langmuir model 
calculating the affinities and rate constants. 
Immunofluorescence staining of gastric cancer cells 
The gastric carcinoma cell line MKN45 was obtained from the Japanese Cancer Research Bank 
(Tsukuba, Japan) and was stably transfected with the full length human ST6GALNAC1 gene or the 
corresponding empty vector pcDNA3.1 as previously described (Marcos et al. 2004). Cells were 
grown in μ-Chamber 12 well glass slides (IBIDI, Martinsried, Germany) and fixed in cold acetone for 
5 min. The mAbs used for immunodetection of Tn-antigen and sialyl-Tn-antigen are described in 
the Materials section. Samples designed for neuraminidase treatment were incubated with 100 μL 
of neuraminidase from C. perfringens type VI (Sigma-Aldrich, Cat. no N3001) diluted 1:20 in 0.1 M 
sodium acetate buffer (pH 5) to a final concentration of 0.1 unit/mL. The incubation was carried out 
for 2 h at 37°C and the reaction was stopped with three washes with cold water. Cells were blocked 
for 1 h at RT with normal goat serum (DAKO, Cat. no X0907) in PBS with 10% BSA. The primary 
antibody, 100 μL (2.5 μg/mL) in PBS containing 5% BSA was added and incubated overnight at 4°C 
and washed with PBS. Anti-His-antibody (R and D Systems, Cat. no MAB050), 100 μL of 2 μg/mL in 
PBS containing 5% BSA, was added to cells stained with scFv and incubated for 1 h at RT. The slides 
were washed in PBS before goat anti-mouse IgG-488 (10 μg/mL, Life Technologies, Cat. no A-
11029) was added and incubated for 1 h at RT. The slides were washed three times in PBS before 
and twice after adding DAPI (0.1 μg/mL, 5 min at RT) for nuclear staining. Slides were examined 
under a Zeiss Imager.Z1 Axio fluorescence microscope (Zeiss, Welwyn Garden City, UK). Images 
were acquired using a Zeiss Axio cam MRm and the AxioVision Release 4.8.1 software. 
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IHC of gastric tissue 
Formalin fixed paraffin embedded tissue samples from patients with gastric carcinoma were 
provided by the department of surgical oncology of the University of Siena, Siena, Italy. Ethical 
permission for the present study was obtained from the local Ethical Committee University of Siena 
from date 22.06.2015. The FFPE sections were deparaffinised and rehydrated before blocking the 
endogenous peroxidases with 3% hydrogen peroxide (H2O2) in methanol. Tissue sections were 
further blocked for 30 min at RT with normal rabbit serum (DAKO, Cat. no X0902) diluted 1:5 in PBS 
containing 10% BSA, followed by incubation with the primary antibodies against Tn-antigen (2.5 
μg/mL) overnight at 4°C. After each incubation with antibodies the slides were rinsed in PBS before 
washing three times in PBS containing 0.02% Tween-20 for 5 min. The anti-His-antibody (R and D 
Systems, Cat. no MAB050), 2 μg/ml in PBS containing 5% BSA, was added to slides coated with 
scFv for 30 min and incubated at RT. Rabbit anti-mouse IgG biotin (1:200 dilution, DAKO, Cat. no 
E0354) was added to all slides for 30 min and incubated at RT. The ABC kit (Vector Labs, 
Burlingame, CA) for 30 min. Finally, sections were stained by 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) and counterstained with Gill's hematoxylin solution. The samples were 
evaluated by a pathologist using a Zeiss Optical Microscope. Immunostaining and the binding 
pattern of G2-D11, GOD3-2C4 and sH1 were evaluated on the 80 cases of human gastric 
carcinomas. 
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FIGURES 
 
 
Figure 1 - Trimer glycopeptide library. General structure of the trimer glycopeptide library with three 
amino acids (X1X2X3) having GalNAc at different positions. Peptides were synthesized on beads and 
cleaved off, before being printed on the array. The library was divided into five different groups based 
on the position of GalNAc (*). The amino acids flanking the GalNAc are presented for each group. The 
number of specific combinations of amino acids tested is specified under “No of combinations.” 
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Fig. 2. Specificity of VVL and antibodies on large trimer amino acid glycopeptide library, printed on 
microarray slides. The library was divided into five groups according to the position of glycosylated 
(GalNAc) serine (S*) and threonine (T*) in relation to other amino acids (X) as described in Figure 1. 
VVL, scFv sH1 and G2-D11, mouse monoclonal GOD3-2C4 and MLS128 antibodies were tested in all 
combinations. Each dot represents a unique sub-library member. Median signals for each group of 
combinations are marked with a blue line and a red circle is highlighting amino acids (X) affecting 
binding of the reagents. (A) Group 1 (XT*T*). (B) Group 2 (T*T*X). (C) Group 3 (XT*S*). (D) Group 4 
(S*T*X). (E) Group 5a (GT*X3, PT*X3, WT*X3, IT*X3, LT*X3, MT*X3, FT*X3, YT*X3 and VT*X3), 
where G2-D11 bound to FT*R, WT*K, YT*W and YT*A, and GOD3-2C4 bound to VT*N, VT*M, 
VT*W, WT*C, WT*D, WT*E, WT*I, WT*M, WT*N, YT*F, YT*M and YT*R. (F) Group 5b (RT*X3, 
HT*X3, KT*X3, DT*X3, ET*X3, ST*X3, TT*X3, NT*X3 and QT*X3), where GOD3-2C4 bound to HT*R. 
This figure is available in black and white in print and in colour at Glycobiology online. 
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Fig. 3. (A) Specificity evaluation of Tn-binding antibodies on glycopeptide microarray. Glycopeptides 
according to Table I were printed on a microarray chip. ScFv G2-D11 was titrated from 10 μg/mL in a 
series of 5, 1, 0.5, 0.1, 0.05 and 0.01 μg/mL, and scFv sH1 from 30 μg/mL in a series of 15, 10, 5, 1, 0.5 
and 0.1 μg/mL, GOD3-2C4 and MLS128 were titrated from 20 μg/mL in a series of 10, 5, 1, 0.5, 0.1 and 
0.05 μg/mL. (B) Specificity evaluation of STn binding antibodies on glycopeptide microarray. 
Glycopeptides according to Table I were printed on a microarray chip. B72.3 was titrated from 20 
μg/mL in a series of 10, 5, 1, 0.5, 0.1, and 0.05 μg/mL. The supernatant containing CC49 was diluted in 
a 2-fold series. 
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Fig. 4. Immunofluorescence staining of mock and ST6GALNAC1 transfected MKN45 cells. (A) 
Staining of mock MKN45 and ST6GALNAC1 transfected MKN45 with GOD3-2C4, G2-D11 and sH1. To 
be able to see the binding pattern of GOD3-2C4, a longer exposure time was required compared to 
G2-D11 and sH1. (B) ST6GALNAC1 transfected MKN45 cells with or without neuraminidase 
treatment and stained with sialyl-Tn-antigen binding antibody B72.3 and Tn-antigen binding scFv G2-
D11. A 630x magnification was used with a shorter exposure time for B72.3 than for G2-D11 as the 
staining with B72.3 at the same exposure time was over expressed. This figure is available in black and 
white in print and in colour at Glycobiology online. 
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Fig. 5. IHC comparison between different antibodies on gastric tissues. Anti-Tn-antigen antibody 
GOD3-2C4, anti-Tn-antigen scFv antibodies G2-D11 and sH1 and positive antibody control (1E3) 
staining of intestinal metaplasia, diffuse type gastric cancer and intestinal type gastric cancer. A 200x 
magnification was used for intestinal metaplasia and 630x for the remaining pictures. This figure is 
available in black and white in print and in colour at Glycobiology online. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
 
 
 
Fig. 6. IHC staining of gastric tissue, using scFv G2-D11. (A, B) Perinuclear staining of normal adjacent 
mucosa. (C, D) Cytoplasmic staining of tumor cells. (E, F) Cytoplasmic and membrane staining of 
tumor cella. (G) Staining of mucin lakes within the carcinoma. A 200x magnification was used for the 
large picture and 630x magnification was used for the inserted picture with the exception of picture C 
with 100x for larger picture and 200x for the inserted picture. (H) Summary of localization of the G2-
D11 staining on 80 cases of gastric carcinoma. This figure is available in black and white in print and in 
colour at Glycobiology online. 
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